- Home
- IDYA vs EVCM Comparison
IDYA vs EVCM Comparison
Compare IDYA & EVCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDYA
- EVCM
- Stock Information
- Founded
- IDYA 2015
- EVCM 2006
- Country
- IDYA United States
- EVCM United States
- Employees
- IDYA N/A
- EVCM N/A
- Industry
- IDYA Biotechnology: Pharmaceutical Preparations
- EVCM EDP Services
- Sector
- IDYA Health Care
- EVCM Technology
- Exchange
- IDYA Nasdaq
- EVCM Nasdaq
- Market Cap
- IDYA 2.3B
- EVCM 2.2B
- IPO Year
- IDYA 2019
- EVCM 2021
- Fundamental
- Price
- IDYA $24.44
- EVCM $11.81
- Analyst Decision
- IDYA Buy
- EVCM Buy
- Analyst Count
- IDYA 14
- EVCM 9
- Target Price
- IDYA $47.75
- EVCM $11.89
- AVG Volume (30 Days)
- IDYA 1.2M
- EVCM 248.3K
- Earning Date
- IDYA 11-03-2025
- EVCM 11-11-2025
- Dividend Yield
- IDYA N/A
- EVCM N/A
- EPS Growth
- IDYA N/A
- EVCM N/A
- EPS
- IDYA N/A
- EVCM N/A
- Revenue
- IDYA $7,000,000.00
- EVCM $710,678,000.00
- Revenue This Year
- IDYA $62.30
- EVCM N/A
- Revenue Next Year
- IDYA $285.58
- EVCM $5.95
- P/E Ratio
- IDYA N/A
- EVCM N/A
- Revenue Growth
- IDYA N/A
- EVCM 14.15
- 52 Week Low
- IDYA $13.45
- EVCM $8.10
- 52 Week High
- IDYA $37.19
- EVCM $12.34
- Technical
- Relative Strength Index (RSI)
- IDYA 49.04
- EVCM 58.83
- Support Level
- IDYA $24.24
- EVCM $11.23
- Resistance Level
- IDYA $25.49
- EVCM $11.75
- Average True Range (ATR)
- IDYA 1.35
- EVCM 0.34
- MACD
- IDYA -0.15
- EVCM 0.02
- Stochastic Oscillator
- IDYA 27.13
- EVCM 73.00
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
About EVCM EverCommerce Inc.
EverCommerce Inc provides tailored Software-as-a-Service solutions for service-based small- and medium-sized businesses (SMBs) in-home services, health services, and fitness & wellness. With a platform serving approximately 708,000 customers across three core verticals, including numerous micro-verticals, their solutions address diverse needs within these sectors. Revenue is mostly generated from the United States. Operating in a single segment, their vertically-tailored SaaS offerings cater to SMBs' specialized demands, enabling them to automate processes, generate business, and enhance customer loyalty. The majority of customers contribute modest revenue, with a small percentage contributing higher amounts.